Table II.
Post-hepatectomy liver function in hepatocellular carcinoma patients with or without postoperative Tα1 therapy.
| Years after surgery | TBIL, µmol/l | ALB, g/l | ALT, U/l | PT, sec |
|---|---|---|---|---|
| Control group | ||||
| 1 year | 12.4 (3.4–506.9) | 42.2±4.9 | 31.0 (8.0–373.0) | 13.3 (10.3–24.2) |
| 2 years | 14.3 (5.2–187.6) | 39.9±4.6 | 33.0 (9.0–219.0) | 13.3 (10.4–17.8) |
| 3 years | 13.3 (5.8–16.0) | 42.3±4.7 | 44.5 (22.0–65.0) | 12.7 (11.0–14.1) |
| Tα1 group | ||||
| 1 year | 10.4 (5.0–134.5) | 44.0±4.3a | 31.5 (10.0–558.0) | 13.0 (10.3–19.1) |
| 2 years | 10.7 (3.8–98.7)a | 45.3±3.1a | 27.5 (6.0–159.0)a | 13.0 (10.2–37.9) |
| 3 years | 9.9 (7.3–12.4)a | 48.6±2.7a | 31.5 (25.0–38.0)a | 11.6 (11.2–12.0)a |
a
P<0.05, Tα1 group vs. control group. Tα1, thymosin α1; TBIL, total bilirubin; ALB, albumin; ALT, alanine aminotransferase; PT, prothrombin time.